(9ci)-5,6-二氟-1H-茚 | 161712-78-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚和异茚
• 中文名称: (9ci)-5,6-二氟-1H-茚
• 英文名称: 5,6-Difluoro-1H-indene
• CAS: 161712-78-3
• 化学式: C₉H₆F₂
• mdl: MFCD18808886
• 分子量: 152.14
• InChiKey: UMKXMUVPBIIAFC-UHFFFAOYSA-N

物化性质

• 沸点：
  183.1±40.0 °C(Predicted)
• 密度：
  1.265±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN<br/>[FR] COMPOSÉS DE THIO-URÉE, GUANIDINE, CYNOGUANIDINE ET D'URÉE BICYCLIQUES UTILES POUR LE TRAITEMENT DE LA DOULEUR
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2014078454A1

  公开（公告）日：2014-05-22

  Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.

  公式I的化合物：或立体异构体、互变异构体、或药用可接受的盐、溶剂化物或前药，其中环A、环C和X如本文定义，是TrkA激酶的抑制剂，可用于治疗可以用TrkA激酶抑制剂治疗的疾病，如疼痛、癌症、炎症/炎症性疾病、神经退行性疾病、某些传染病、舍格伦综合症、子宫内膜异位症、糖尿病周围神经病、前列腺炎和盆腔疼痛综合症。
• [EN] COMPOUNDS FOR OPTICALLY ACTIVE DEVICES<br/>[FR] COMPOSÉS POUR DISPOSITIFS OPTIQUEMENT ACTIFS
  申请人：MERCK PATENT GMBH

  公开号：WO2020212543A1

  公开（公告）日：2020-10-22

  The present invention relates to novel ophthalmic devices comprising polymerized compounds comprising a photoactive unit, said polymerized compounds, and special monomer compounds being particularly suitable for compositions and ophthalmic devices.

  本发明涉及包含光活性单元的聚合化合物的创新眼科设备，所述聚合化合物，以及特别适合用于组合物和眼科设备的特殊单体化合物。
• [EN] SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS<br/>[FR] DÉRIVÉS DE SPIROCYCLOHEXANE, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET LEURS UTILISATIONS EN TANT QU'INHIBITEURS ANTI-APOPTOTIQUES
  申请人：SERVIER LAB

  公开号：WO2022152705A1

  公开（公告）日：2022-07-21

  Compounds of Formula (I) wherein R1, R3, R11, R12, X, Y1, Y2, Y3, Y4and formula (II) are as defined in the description. Medicaments.

  公式（I）化合物，其中R1、R3、R11、R12、X、Y1、Y2、Y3、Y4和公式（II）如描述中所定义。药物。
• Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain
  申请人：Array BioPharma Inc.

  公开号：US10351575B2

  公开（公告）日：2019-07-16

  Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.

  式 I 的化合物或其立体异构体、同系物或药学上可接受的盐、溶液剂或原药，其中环 A、环 C 和 X 如本文所定义，是 TrkA 激酶的抑制剂，可用于治疗可使用 TrkA 激酶抑制剂治疗的疾病，如疼痛、癌症、炎症/炎症性疾病、神经退行性疾病、某些传染性疾病、Sjogren 综合征、子宫内膜异位症、糖尿病周围神经病变、前列腺炎和盆腔疼痛综合征。
• Glycolate oxidase inhibitors for the treatment of disease
  申请人：BIOMARIN PHARMACEUTICAL INC.

  公开号：US11384055B2

  公开（公告）日：2022-07-12

  Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme glycolate oxidase (GO). Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

  本文描述的是化合物、制造此类化合物的方法、含有此类化合物的药物组合物和药剂，以及使用此类化合物治疗或预防与乙醛酸氧化酶（GO）相关的疾病或紊乱的方法。此类疾病或紊乱包括，例如，与产生过量草酸盐有关的乙醛酸代谢紊乱，包括原发性高草酸尿症。